Viking Therapeutics misses Q3 profit estimates

Viking Therapeutics

22/10/2025 21:27

Overview

Viking Therapeutics reports Q3 net loss of $90.8 mln, missing analyst expectations

Company maintains strong cash position of $715 mln to support ongoing clinical trials

VK2735 Phase 2 VENTURE study shows up to 12.2% weight loss, meeting primary endpoints

Outlook

Company expects to complete VANQUISH-1 enrollment by end of 2025

Viking plans to meet with regulators in Q4 to discuss oral VK2735

Company plans to file IND for amylin agonist program in 1Q26

Result Drivers

VENTURE STUDY RESULTS - Phase 2 VENTURE study of VK2735 achieved primary and secondary endpoints with up to 12.2% weight loss

VANQUISH TRIALS PROGRESS - Phase 3 VANQUISH trials for VK2735 in obesity are proceeding on schedule with strong enrollment

CASH POSITION - Strong cash position of $715 mln supports ongoing clinical trials and development programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Miss
-$0.81
-$0.67 (16 Analysts)
Q3 Net Income
Miss
-$90.78 mln
-$80.87 mln (14 Analysts)
Q3 Income from Operations
Miss
-$98.56 mln
-$86.14 mln (14 Analysts)
Q3 Operating Expenses
$98.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Viking Therapeutics Inc is $100.00, about 67% above its October 21 closing price of $32.98

Press Release: ID:nPnbnvNM5a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)